Foyston, Gordon, & Payne Inc Pfizer Inc Transaction History

Foyston, Gordon, & Payne Inc

$396 Million
Q2 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$25.89 - $29.73 $32,673 - $37,519	-1,262 Reduced 1.79%	69,262 $1.92 Million
Q4 2023 Feb 07, 2024	BUY	$26.13 - $33.94 $45,962 - $59,700	1,759 Added 2.56%	70,524 $2.03 Million
Q3 2023 Oct 26, 2023	BUY	$32.09 - $37.51 $260,346 - $304,318	8,113 Added 13.38%	68,765 $2.28 Million
Q2 2023 Aug 01, 2023	SELL	$36.12 - $41.79 $38,576 - $44,631	-1,068 Reduced 1.73%	60,652 $2.22 Million
Q1 2023 May 03, 2023	SELL	$39.39 - $51.28 $734,899 - $956,730	-18,657 Reduced 23.21%	61,720 $2.52 Million
Q4 2022 Feb 09, 2023	SELL	$41.75 - $54.5 $3,757 - $4,905	-90 Reduced 0.11%	80,377 $4.12 Million
Q3 2022 Nov 04, 2022	BUY	$43.76 - $53.42 $733,811 - $895,799	16,769 Added 26.33%	80,467 $3.52 Million
Q2 2022 Aug 11, 2022	SELL	$46.53 - $55.17 $1.02 Million - $1.21 Million	-21,941 Reduced 25.62%	63,698 $4.28 Million
Q1 2022 Apr 27, 2022	SELL	$45.75 - $56.69 $303,734 - $376,364	-6,639 Reduced 7.19%	85,639 $4.43 Million
Q4 2021 Feb 11, 2022	SELL	$41.32 - $61.25 $71,029 - $105,288	-1,719 Reduced 1.83%	92,278 $5.45 Million
Q3 2021 Nov 12, 2021	SELL	$39.25 - $50.42 $1.42 Million - $1.82 Million	-36,116 Reduced 27.76%	93,997 $4.04 Million
Q2 2021 Aug 06, 2021	SELL	$35.91 - $40.68 $597,542 - $676,915	-16,640 Reduced 11.34%	130,113 $5.1 Million
Q1 2021 May 14, 2021	SELL	$33.49 - $37.77 $1.51 Million - $1.7 Million	-45,058 Reduced 23.49%	146,753 $5.32 Million
Q4 2020 Feb 12, 2021	SELL	$33.47 - $42.56 $440,866 - $560,600	-13,172 Reduced 6.43%	191,811 $7.06 Million
Q3 2020 Nov 12, 2020	SELL	$31.75 - $37.25 $277,622 - $325,714	-8,744 Reduced 4.09%	204,983 $7.52 Million
Q2 2020 Aug 14, 2020	BUY	$30.12 - $36.54 $870,498 - $1.06 Million	28,901 Added 15.64%	213,727 $6.99 Million
Q1 2020 May 15, 2020	SELL	$27.03 - $38.62 $1.23 Million - $1.76 Million	-45,447 Reduced 19.74%	184,826 $6.03 Million
Q4 2019 Feb 14, 2020	SELL	$32.92 - $37.36 $159,168 - $180,635	-4,835 Reduced 2.06%	230,273 $9.02 Million
Q3 2019 Nov 14, 2019	BUY	$32.49 - $42.13 $289,355 - $375,209	8,906 Added 3.94%	235,108 $8.45 Million
Q2 2019 Aug 15, 2019	SELL	$36.98 - $41.52 $20,486 - $23,002	-554 Reduced 0.24%	226,202 $9.8 Million
Q1 2019 May 14, 2019	SELL	$37.5 - $41.2 $1.55 Million - $1.7 Million	-41,311 Reduced 15.41%	226,756 $9.63 Million
Q4 2018 Feb 08, 2019	SELL	$38.47 - $43.86 $857,227 - $977,332	-22,283 Reduced 7.67%	268,067 $11.7 Million
Q3 2018 Nov 02, 2018	SELL	$34.47 - $41.81 $502,469 - $609,464	-14,577 Reduced 4.78%	290,350 $12.8 Million
Q2 2018 Aug 10, 2018	BUY	$32.98 - $35.16 $15,665 - $16,701	475 Added 0.16%	304,927 $11.1 Million
Q1 2018 May 14, 2018	SELL	$31.91 - $37.02 $541,065 - $627,711	-16,956 Reduced 5.28%	304,452 $10.8 Million
Q4 2017 Feb 14, 2018	BUY	$33.26 - $35.29 $346,103 - $367,227	10,406 Added 3.35%	321,408 $11.6 Million
Q3 2017 Nov 14, 2017	SELL	$31.0 - $34.15 $2.68 Million - $2.95 Million	-86,292 Reduced 21.72%	311,002 $11.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	397,294	397,294 $13.3 Million

Others Institutions Holding PFE

# of Institutions

3,222

Shares Held

3.71B

Call Options Held

73.2M

Put Options Held

108M

Vanguard Group Inc Valley Forge, PA

511M
Shares

$14.6 Billion
0.28% of portfolio
Black Rock Inc. New York, NY

424M
Shares

$12.1 Billion
0.27% of portfolio
State Street Corp Boston, MA

287M
Shares

$8.2 Billion
0.36% of portfolio
Wellington Management Group LLP Boston, MA

166M
Shares

$4.75 Billion
0.85% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

117M
Shares

$3.35 Billion
0.63% of portfolio

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $160B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Foyston, Gordon, & Payne Inc, based on Form 13F filings with the SEC.

News

Stay updated on Foyston, Gordon, & Payne Inc with notifications on news.

Account